Vensana Capital I GP, LLC
CIK: 0001854073
Vensana Capital I GP, LLC's purchase track record
Vensana Capital I GP, LLC has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/9/2026 | SGP | $2.64M | -9.2% | -3.9% | +11.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SGP | ▼ Sell | Other | 359,255 | — | 2/9/2026 | View on chart |
| SGP | ▲ Buy | Open Market | 165,000 | $2.6M | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 548,067 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 1,690,230 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 548,067 | — | 2/9/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
SpyGlass Pharma Schedules Upcoming Investor Conference Participation
SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.
SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.